What changed
FACT: In June 2026 FDA issued a cluster of class II special-controls classification orders — monitor for opioid-induced impairment of oxygenation (June 30), computerized behavioral therapy device for fibromyalgia (June 26), ML-based quantitative imaging software (June 17), preeclampsia prognostic test, SARS-CoV-2 serology, infant supine sleep system, and several endoscopic devices (all cited). Each order codifies special controls and opens a 510(k) pathway that pulls new, often software-first, firms into FDA's recurring device regime: annual establishment registration with user fees, device listing, UDI/GUDID records, complaint files under 21 CFR 820.198, and MDR readiness under 21 CFR 803.
Why now
FACT: The orders are days-to-weeks old, so a fresh cohort of first-time registrants in wearables/software-adjacent categories will appear in FDA's public registration & listing database as they file. HYPOTHESIS: These founders are software people without regulatory-affairs staff, and the window to become their compliance vendor is at first registration, before an RA consultancy locks them in.
Converging signals
Multiple simultaneous class II classification orders across anesthesiology (opioid oxygenation monitors), neurology (digital therapeutics), radiology (ML imaging software), and IVDs (all FORCED BUYER evidence, similarity 0.74-0.77) converge with the pattern that FDA's establishment registration/listing data is public and downloadable, making the obligated class enumerable. No PAIN or HIRING/SPEND evidence was provided in demand_evidence — the demand case rests entirely on the mandate structure, which is strong but one-legged.
Customer pain
FACT (from the regulatory structure): lapse in annual registration or listing renders the device misbranded under FD&C Act §502(o) — it cannot legally be marketed. Small firms must also maintain complaint files and file MDRs within 30 days (5 for certain events), which software founders typically don't know. HYPOTHESIS: single-listing registrants routinely miss the Oct 1–Dec 31 renewal window, underpay/overpay the annual user fee (~$9,280 FY2026 scale), and have no complaint-handling SOP until an inspection or MDR event exposes it. This pain is inferred, not evidenced in the input — no founder complaints were supplied.
Who pays
The registrant firm itself: US-based small class II device companies with exactly one listed device and no RA hire. HYPOTHESIS: several thousand such firms exist in the public data; the one-week test in the convergence description is the right way to size it. Secondary payers: new entrants triggered by the June 2026 orders who have not yet registered.
Solved today
FACT-ADJACENT (well-known market structure, not in supplied sources — treat as high-confidence inference): Registrar Corp, Emergo by UL, and similar firms already sell registration/renewal/US-Agent services, including to small and foreign firms, at a few hundred to low-thousands of dollars per year; RA consultants handle MDR and complaint files hourly at $150-350/hr; eQMS platforms (Greenlight Guru, Qualio, Rimsys) sell $10k+/yr software aimed at funded medtech.
Why current solutions are bad
HYPOTHESIS: incumbents split the job — registration mills do the filing but not vigilance (complaint file, MDR SOPs, UDI upkeep), consultants do vigilance but at hourly rates small firms avoid, and eQMS platforms are overkill for a one-device firm. Nobody sells a single flat-fee 'stay-legal file' for the one-device tail. CAUTION: this gap is the weakest link in the thesis — Registrar Corp's small-firm pricing may already cover most of it, which is exactly the falsification test named in the convergence.
Proposed product
A 'Device Compliance File' subscription: (1) monitored renewal calendar keyed to the firm's actual FURLS registration and FY user-fee windows, (2) listing/UDI/GUDID record checks against FDA's public data with drift alerts, (3) a maintained complaint-file system (templates + intake form + log) mapped to 21 CFR 820.198, (4) MDR decision-tree triage support and 3500A prep checklists, (5) an annual audit-ready binder. Built as a thin SaaS over FDA's public data feeds plus templated documents — not hourly consulting.
MVP version
No product build first. Week 1: download FDA's establishment registration & listing data files, filter to US firms with exactly one listed device, dedupe against parent companies, and produce the contact list. Weeks 1-2: 40-email probe offering a flat-fee registration+vigilance file; target ≥2 discovery calls (the convergence's own testable prediction). If validated, MVP is a Notion/Docs template pack + a renewal-monitoring script + a Stripe subscription — 2-3 weeks of AI-assisted build.
30-day build
Complete the enumeration and the 40-email probe; interview every respondent on what they currently pay Registrar Corp-style vendors and what they fear (inspection, MDR miss, renewal lapse); price-test $149-299/mo vs $1,500-2,500/yr flat; simultaneously check the falsifiers: incumbent small-firm pricing and the share of single-listing registrants that are shells of larger firms.
60-day build
If ≥2 calls convert to ≥1 paying pilot: ship the monitoring script (public data diff + renewal calendar), deliver the first three compliance files manually (productized service), and refine the MDR triage checklist with a licensed RA consultant on a small retainer to backstop liability and credibility.
90-day revenue plan
Target 5-10 subscribers at ~$200/mo or ~$2,000/yr flat by day 90 ($1,000-2,000 MRR equivalent) via continued cold outreach to the enumerated list, prioritizing registrants in the newly classified June 2026 categories where the entire cohort is new to the regime. Realistic ramp given the founder's runway; this is a 90-180 day first-revenue play, not 30-day.
Distribution path
Cold email/LinkedIn to a list FDA itself publishes — official correspondent names and addresses are in the registration data. This matches the founder's demonstrated-value sales style: lead each email with a free, specific finding about the recipient's own registration record (e.g., renewal window, listing inconsistency). No ad spend, no marketplace, no channel gatekeeper.
Pricing hypothesis
$149-299/mo subscription or $1,995/yr flat 'compliance file' with a $495 setup. Anchor against the ~$9,280 annual FDA user fee they already pay and the ~$300/hr RA consultant alternative. Per-filing add-ons (MDR prep, listing corrections) preserve the founder's proven per-transaction motif.
Technical difficulty
Low-moderate. FDA registration/listing and GUDID data are public downloads; the monitoring layer is scripting the founder already does well. The hard part is regulatory content quality (MDR decision trees, complaint SOPs), which is bounded and can be licensed/reviewed by a contracted RA professional. He is NOT building against a submission portal here — FURLS filing stays in the customer's hands, which weakens the ELDT analogy.
Legal / regulatory risk
Moderate and must be managed: advising on MDRs edges into regulatory consulting; a wrong call could leave a customer misbranded or in MDR violation. Mitigations: position as templates+monitoring+deadline management, not legal/regulatory advice; contract RA-professional review; E&O insurance. Selling TO regulated firms is not itself regulated, but the trust bar is real for a founder without RA credentials.
Platform dependency
Low. Depends only on FDA continuing to publish registration/listing data (long-standing, statutorily grounded practice). No app store, no API gatekeeper.
Founder fit
Strong on pattern (read a mandate, enumerate the obligated class from government data, monetize compliance) — the proven ELDT edge, and the accumulated lesson (confidence 0.80) that government-portal mandate shapes fit him best applies. Weaker than ELDT on two counts: he does not perform the filing per-transaction (registrants file FURLS themselves), and he has no medical-device RA credibility, in a domain where buyers are trust-sensitive. Net: high fit, one notch below a true submission-portal play.
Breakout potential
Moderate-good. The 'enumerable forced-buyer compliance file' pattern repeats across FDA device categories, food facility registration, and other agency registries; the monitoring engine and outreach machine are reusable. Could grow into a small-registrant compliance platform, but incumbents cap the ceiling.
Final recommendation
TEST, don't build. The mandate structure is real and the buyer list is literally downloadable, but the competitive gap is unproven and the ELDT analogy is imperfect (no per-transaction portal wedge). Run the convergence's own one-week falsification — enumerate single-listing US registrants, price-shop Registrar Corp/Emergo small-firm packages, and send the 40-email probe. Build only if ≥2 discovery calls materialize AND incumbent small-firm pricing leaves a vigilance-shaped gap above ~$1k/yr.
Next action
Today: download FDA's establishment registration & listing public data export, filter to US firms with exactly one listed device, and produce the count plus a 40-contact probe list; in parallel, get published small-firm pricing from Registrar Corp and one RA consultancy to test the kill hypothesis.